Literature DB >> 10997480

Estrogen and cerebral blood flow: a mechanism to explain the impact of estrogen on the incidence and treatment of Alzheimer's disease.

R A Greene1.   

Abstract

OBJECTIVE: Women are three times as likely to develop late-onset Alzheimer's Disease (AD) as are age-matched men. In the perimenopausal period, women typically have profound hypoestrogenism associated with vasomotor episodes. The pattern of AD development in women resembles the hormonal changes that occur in the perimenopausal period; the risk of AD is lower in menopausal women taking estrogen replacement therapy (ERT), and ERT is associated with clinical improvement in AD patients. Further, ERT has been shown to augment the therapeutic benefits of medications designed to treat AD. To understand better the relationship between ERT, hot flushes and AD, a pilot study was conducted at UCLA-Harbor Medical Center. PATIENTS AND METHODS: Twelve healthy menopausal women experiencing daily hot flushes and not on ERT were recruited to participate in a clinical study. Each patient underwent regional cerebral blood flow (CBF) measurement using single-photon emission computed tomography (SPECT) at baseline and during a hot flush episode. Patients were then randomized to receive either 0.625 mg or 1.25 mg conjugated equine estrogens (CEE) daily. During the sixth week of ERT, each patient had a repeat SPECT study. Baseline SPECT data were compared with ERT data.
RESULTS: Baseline examinations demonstrated CBF patterns commonly seen in patients with Alzheimer's disease. There was a global improvement in CBF associated with ERT, an average gain of 22% over baseline. Improvements were most dramatic in the temporal and parietal regions of the brain. The cortical CBF demonstrated a mean increase of 9.2 mL/100 g/min (P < .01).
CONCLUSIONS: CBF is diminished in hypoestrogenic women, with regional patterns resembling those of patients with mild to moderate AD. Cerebral circulation tends to be further compromised during hot flush episodes. This mechanism could be the initiating event in the metabolic process that results in dementia of the Alzheimer's type, and thus serve as the link between hypoestrogenism and neurodegenerative diseases. In this study, ERT reversed these detrimental blood flow changes back to a normal pattern after only 6 weeks of CEE therapy. With improved blood flow, the brain is protected from the metabolic injury associated with hypoxia. The study is currently being repeated with a larger population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997480

Source DB:  PubMed          Journal:  Int J Fertil Womens Med        ISSN: 1534-892X


  10 in total

1.  Enhanced neuroactivation during verbal memory processing in postmenopausal women receiving short-term hormone therapy.

Authors:  Carol C Persad; Jon-Kar Zubieta; Tiffany Love; Heng Wang; Anne Tkaczyk; Yolanda R Smith
Journal:  Fertil Steril       Date:  2008-08-09       Impact factor: 7.329

2.  Impact of combined estradiol and norethindrone therapy on visuospatial working memory assessed by functional magnetic resonance imaging.

Authors:  Yolanda R Smith; Tiffany Love; Carol C Persad; Anne Tkaczyk; Thomas E Nichols; Jon-Kar Zubieta
Journal:  J Clin Endocrinol Metab       Date:  2006-08-15       Impact factor: 5.958

Review 3.  GPR30 is positioned to mediate estrogen effects on basal forebrain cholinergic neurons and cognitive performance.

Authors:  R Hammond; R B Gibbs
Journal:  Brain Res       Date:  2010-12-05       Impact factor: 3.252

Review 4.  Estrogen therapy and cognition: a review of the cholinergic hypothesis.

Authors:  Robert B Gibbs
Journal:  Endocr Rev       Date:  2009-12-17       Impact factor: 19.871

Review 5.  Estrogen therapy: is time of initiation critical for neuroprotection?

Authors:  Barbara B Sherwin
Journal:  Nat Rev Endocrinol       Date:  2009-11       Impact factor: 43.330

Review 6.  Enhanced Neuroactivation during Working Memory Task in Postmenopausal Women Receiving Hormone Therapy: A Coordinate-Based Meta-Analysis.

Authors:  Ke Li; Xiaoyan Huang; Yingping Han; Jun Zhang; Yuhan Lai; Li Yuan; Jiaojiao Lu; Dong Zeng
Journal:  Front Hum Neurosci       Date:  2015-02-11       Impact factor: 3.169

7.  Poor cerebrovascular function is an early marker of cognitive decline in healthy postmenopausal women.

Authors:  Rachel H X Wong; Hamish M Evans; Peter R C Howe
Journal:  Alzheimers Dement (N Y)       Date:  2016-08-03

8.  Sex-specific risk of cardiovascular disease and cognitive decline: pregnancy and menopause.

Authors:  Virginia M Miller; Vesna D Garovic; Kejal Kantarci; Jill N Barnes; Muthuvel Jayachandran; Michelle M Mielke; Michael J Joyner; Lynne T Shuster; Walter A Rocca
Journal:  Biol Sex Differ       Date:  2013-03-28       Impact factor: 5.027

9.  Gender based variation in cognitive functions in adolescent subjects.

Authors:  Sunita Mittal; Punam Verma; Nidhi Jain; Shallu Khatter; Ankita Juyal
Journal:  Ann Neurosci       Date:  2012-10

10.  Clinical Evaluation of Effects of Chronic Resveratrol Supplementation on Cerebrovascular Function, Cognition, Mood, Physical Function and General Well-Being in Postmenopausal Women-Rationale and Study Design.

Authors:  Hamish Michael Evans; Peter Ranald Charles Howe; Rachel Heloise Xiwen Wong
Journal:  Nutrients       Date:  2016-03-09       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.